Pfizer
Sources: the KBO register on 21-11-2026; the National Bank, annual accounts to 30-11-2025 filed on 02-06-2026; the Belgian Official Gazette, latest deed of 04-08-2026.
- Base your decision on your own payment experience with the company or on securities.
Grounds
the facts the verdict rests on, each with its source- In the year to 30-11-2025, Pfizer had a turnover of €358.3m and a net profit of €3.7m.Annual accounts to 30-11-2025 page 2
- Suppliers waited 40 days on average for their money in the year to 30-11-2025, 67 days shorter than in the year to 30-11-2024. Customers paid after 126 days.Annual accounts to 30-11-2024 and to 30-11-2025 page 2
- The last five annual accounts came in on time. The accounts to 30-11-2025 were filed 28 days before the end of the term.National Bank, filing of 02-06-2026 page 5
Representation
Two directors jointly represent Pfizer. The directors are , and .
Articles of association, Belgian Official Gazette of 19-01-2026, deed 26007992
Ownership
. includes Pfizer in its consolidated accounts. According to the deed of 10-07-2019, . holds all the shares.
LEI register, deed 19091888
Financial situation
Annual accounts 2021 to 2025, as filed with the National Bank
Turnover and net resultin €m
Equity and debtsin €m
Payment termsin days
| Financial year | 2021 | 2022 | 2023 | 2024 | 2025 | Trend |
|---|---|---|---|---|---|---|
| Results | ||||||
| Turnover | €469.5m | €548.2m | €349.4m | €336.5m | €358.3m | |
| Operating result | €27.1m | €29.8m | €20.7m | €36.2m | €15.1m | |
| Net result | €19.5m | €21.6m | €12.9m | €23.2m | €3.7m | |
| Balance sheet at the closing date | ||||||
| Equity | €118.8m | €90.4m | - | - | - | |
| Debts | €132.2m | €183.5m | €275.7m | €346.0m | €226.6m | |
| Debts due within one year | €130.1m | €182.6m | €249.2m | €338.4m | €224.7m | |
| Cash | €40.7m | €724,690 | €21.9m | €21.3m | €23.9m | |
| Balance sheet total | €254.7m | €285.3m | €383.4m | €474.6m | €377.4m | |
| Operations | ||||||
| Employees in full-time equivalents | 333.4 | 336.3 | 338.2 | 323.0 | 297.0 | |
| Customer credit | 85 days | 91 days | 179 days | 175 days | 126 days | |
| Supplier credit | 54 days | 19 days | 7 days | 107 days | 40 days | |
| Ratios | ||||||
| Solvency | 46.7% | 31.7% | - | - | - | |
| Liquidity | 1.88 | 1.50 | 1.49 | 1.37 | 1.63 | |
Source: Annual accounts to 30-11-2025, full format, filed on 02-06-2026 (2026-00137670); Annual accounts to 30-11-2024, full format, filed on 23-05-2025 (2025-00110685); Annual accounts 2021 to 2023, filed from 01-06-2022 to 21-05-2024 (2022-20046669, 2023-00098666, 2024-00094385).
The operating result of 2025 is 58% lower than in 2024.
Debts fell by €119.4m in 2025.
The annual accounts to 30-11-2025 state no amount of overdue tax or social security (RSZ) debts.
Board, signature and ownership
Position on 21-11-2026 according to the deeds in the Belgian Official Gazette and the annual accounts
Who represents the company
Two directors jointly represent Pfizer. The directors are , and .
Articles of association, Belgian Official Gazette of 19-01-2026, deed 26007992
Board
three directors and one statutory auditor in officeOwnership and group
Shareholders
. includes Pfizer in its consolidated accounts. includes Pfizer in its consolidated accounts. According to the deed of 10-07-2019, . holds all the shares.
LEI register, annual accounts 30-11-2014, deed 19091888
Board changes
and resign. appointed. Discharge granted to . General meeting of 01-07-2026.
Gazette, deed 26099381Power of attorney granted to . Board meeting of 13-01-2026.
Gazette, deed 26045964New managing director. appointed, resigned. Discharge granted to . Board meeting of 24-11-2025.
Gazette, deed 26007992(director) and (statutory auditor) reappointed. General meeting of 21-05-2025.
Gazette, deed 25080098resigns as managing director. appointed as managing director. acts as permanent representative.
Gazette, deed 25037930Powers of attorney granted to , and 7 others. Board meeting of 27-04-2023.
Gazette, deed 23068149Holdings
Pfizer has 2 holdings (own accounts to 30-11-2014).
| Country | Company | Year | Equity | Result | |
|---|---|---|---|---|---|
| Belgium 2 | |||||
| BE | 0.08%dissolved | 2021 | €2.7m | result -€23,058 | |
| BE | 0.04% | 2014 | €514,810 | result -€5,729 | |
Source: List of holdings in its own accounts to 30-11-2014. Holdings that file themselves stand with their latest accounts, the others with the amounts of that list, in their own currency.
Events and comparison
The latest events, newest first
Annual accounts 2025 filed, 28 days before the deadline.
NBB filingAnnual accounts 2024 filed, 38 days before the deadline.
NBB filingAnnual accounts 2023 filed, 40 days before the deadline.
NBB filingAnnual accounts 2022 filed, 38 days before the deadline.
NBB filingNew managing director. appointed, resigned. General meeting of 03-10-2022.
Gazette, deed 22142900reappointed as statutory auditor. General meeting of 10-06-2022.
Gazette, deed 22099635Annual accounts 2021 filed, 29 days before the deadline.
NBB filingresigns. and appointed. General meeting of 18-05-2021. Published again on 26-08-2021.
Gazette, deed 21092974Annual accounts 2020 filed, 30 days before the deadline.
NBB filingAnnual accounts 2019 filed, 1 day before the deadline.
NBB filingAmendment of the articles. Auditor report: €56,018,500. Capital of €39,688,620.47, 216,166 shares. General meeting of 30-04-2020.
Gazette, deed 20322673General meeting of 21-01-2020. Published again on 11-03-2020.
Gazette, deed 20027504. holds all the shares.
Gazette, deed 19091888, , and (statutory auditor). acts as permanent representative. General meeting of 15-05-2019.
Gazette, deed 19079915The return on assets of Pfizer, 1.0%, is higher than at 29% of the 3,801 companies filing full accounts in wholesale trade (NACE 46) in 2025.
Other findings
Peppol
Reachable for e-invoices since 14-10-2025, under 0208:0401994823.
Sanctions lists
Sources and method
Where each fact in this report comes from
| Source | What | Date | Reference |
|---|---|---|---|
| KBO register | Registration, legal situation, activity, establishment units | 21-11-2026 | KBO 0401.994.823 |
| National Bank of Belgium | Annual accounts to 30-11-2025, full format | 02-06-2026 | 2026-00137670 |
| National Bank of Belgium | Annual accounts to 30-11-2024, full format | 23-05-2025 | 2025-00110685 |
| National Bank of Belgium | Annual accounts 2021 to 2023 | 01-06-2022 to 21-05-2024 | 2022-20046669, 2023-00098666, 2024-00094385 |
| Belgian Official Gazette | Board | 04-08-2026 | deed 26099381 |
| Belgian Official Gazette | Board | 02-04-2026 | deed 26045964 |
| Belgian Official Gazette | Articles of association with the signing rule | 19-01-2026 | deed 26007992 |
| Belgian Official Gazette | All shares held by one shareholder | 10-07-2019 | deed 19091888 |
| Peppol Directory | Registration for e-invoices | 14-10-2025 | 0208:0401994823 |
| Sanctions lists EU, UN, US (OFAC) and UK | Comparison of the name | 19-11-2026 | |
| Checked | Checked score, bankruptcy probability, credit, comparable companies | 20-11-2026 | bankruptcy model of 2 October 2026 |
Method
Bankruptcy probability. The probability that the company goes bankrupt within 12 months, estimated from the KBO register, the annual accounts and the Gazette with the bankruptcy model of 2 October 2026, computed on 20-11-2026.
Payment terms. Supplier credit is the debt to suppliers divided by the year's purchases, times 365. Customer credit is the same for what customers still owe, against turnover.
The scores and ratios are Checked's own calculations, not a credit decision.